Expression Rate Of Matrix Metalloproteinase-9 Research Articles

Association of MMP-9 and PCNA Protein Expression in Osteosarcoma are Associated with Clinical Stage, Metastasis, and Prognosis

ABSTRACT Present work studies the expressions of MMP-9 and PCNA in osteosarcoma patients and its correlation with clinical stage. 53 specimens of osteosarcoma were surgically removed and 28 osteochondroma tissues were used for immunohistochemical staining to detect the expression of proliferating cell nuclear antigen (PCNA) as well as matrix metalloproteinase-9 (MMP-9). The expression rates of MMP-9, as well as PCNA, were 75.5 percent and 86.8 percent in osteosarcoma, while were 10.7 percent and 7.5 percent in osteochondroma, respectively, which was statistically significant (P<0.05). The expression levels of MMP-9, PCNA, and the total survival time were connected with the Enneking stage. It shows an upward trend for the expression levels of PCNA and MMP- 9 in osteosarcoma tissues. The expression levels of MMP-9 and PCNA are related to the clinical stage, metastasis, and prognosis.

Expression and significance of human ether-a-go-go-related gene protein and matrix metalloproteinase-9 in gastric cancers

Objective To investigate the expression of human ether-a-go-go-related gene (HERG1) protein and matrix metalloproteinase-9 (MMP-9) in gastric carcinoma and their correlation with prognosis of gastric carcinoma. Methods Reverse transcription and polymerase chain reaction (PCR) assay and Western blotting were used to detect the expression of HERG1 and MMP-9 in 80 cases of gastric carcinomas and corresponding normal gastric tissues, and the patients were followed up. Results The positive expression rate of HERG1 and MMP-9 was 60% and 55% respectively. There was significant correlation between the positive expression rate of MMP-9 with depth of invasion, TNM stage, differention, lymphatic and distant matastasis. The positive rate of HERG1 was correlated with lymphatic and distant metastasis. Conclusion HERG1 protein and MMP-9 expression in gastric carcinoma appears to be well-characterized indicators of prognosis and metastasis and may play an important role in the tumor invasion and metastasis. Key words: Gastric carcinoma; Human ether-a-go-go-related gene protein; Matrix metalloproteinase-9; Metastasis

Differences of malignant proliferation and infiltrating growth related molecular changes in different pathological types of glioma

Objective To investigate the distribution of the cell cycle alteration and cell migration as well as infiltrating growth process and related genetic changes in each grade and each molecular subtype of gliomas. Methods A total of 300 glioma specimens(WHO grade Ⅱ-Ⅳ)in Chinese Glioma Genome Atlas(CGGA)were collected. Its tissue RNA and DNA were extract respectively. Sanger sequencing was used to detect the mutation status of PTEN, p53, and TERT promoter. The expression levels of MET and matrix metalloproteinase 9(MMP-9)were derived from whole-genome RNA microarray expression profile. The distribution differences of the mutations of PTEN, p53, TERT promoter and high expression of MET and MMP-9 were compared in each level and each molecular subtypes of glioma. Results (1)In WHO grade Ⅱ, Ⅲ and Ⅳ, the mutation frequencies of PTEN were 2.8%(2/72), 5.0%(1/20), and 23.0%(20/87), respectively; the mutation rates of p53 were 28.0%(21/75), 10.0%(2/20), and 20.7%(18/87), respectively; the mutation rates of TERT promoter were 30.2%(26/86), 47.1%(8/17), and 46.8%(29/62), respectively; the incidences of MET high expression were 28.9%(35/121), 33.3%(17/51), and 37.5%(48/128), respectively; and the high expression rates of MMP-9 were 3.3%(4/121), 39.2%(20/51), and 59.4%(76/128), respectively. There were significant differences in each grade of gliomas between the mutation rate of PTEN and the high expression rate of MMP-9(all P<0.01).(2)The mutation rates of PTEN in the proneural type, neural type, classical type and molecular type of mesenchymal glioma were 1.9%(1/52), 12.5%(4/32), 15.0%(3/20), and 20.0%(15/75), respectively; the mutation rates of p53 were 34.0%(18/53), 6.1%(2/33), 40.0%(8/20), and 17.1%(13/76), respectively; the mutation rates of TERT promoter were 37.5%(21/56), 34.5%(10/29), 31.3%(5/16), and 45.1%(23/51), respectively; the MET high expression rates were 25.6%(21/82), 34.5%(19/55), 28.9%(11/38), and 40.0%(38/95), respectively; the MMP-9 high expression rates were 9.8%(8/82), 1.8%(1/55), 44.7%(17/38), and 68.4%(65/95), respectively. There were significant differences in the mutation rates of PTEN and p53, and the MMP-9 high expression rates among each molecular subtype of glioma(all P<0.05). Conclusions The mutation rate of PTEN and the high expression rates of MMP-9 were associated with the malignant degree of gliomas. The differences of the mutation rates of PTEN and p53, and the high expression rates of MMP-9 in each molecular subtype of gliomas suggested that they could represent the molecular pathologic features of the specific molecular subtypes of gliomas. Key words: Glioma; Pathology; Molecular subtype; Malignant proliferation; Infiltrating growth

Elevated matrix metalloproteinase-9 expression may contribute to the pathogenesis of bladder cancer.

The present study investigated the potential association between matrix metalloproteinase-9 (MMP-9) expression and the pathogenesis of bladder cancer. The present study reviewed previous studies published in Chinese and English using predefined selection criteria, which identified high-quality studies concerning MMP-9 and bladder cancer. Statistical analyses of the data were conducted using Comprehensive Meta-Analysis software version 2.0. In total, 23 case-control studies were selected, which consisted of 1,040 bladder cancer patients and 244 healthy controls. The expression rates and protein levels of MMP-9 were significantly increased in bladder cancer patients compared with the healthy controls, which was demonstrated using immunohistochemistry (IHC) and enzyme-linked immunosorbent assay-based methods. Furthermore, the expression rate of MMP-9 in histological G1/G2 grade bladder cancer tumors was significantly decreased compared with G3 tumors. Subgroup analysis based on ethnicity demonstrated that the rate of MMP-9 protein expression between bladder cancer patients and healthy controls was significantly different in African, Asian and Caucasian patients, which was identified using IHC. The MMP-9 protein levels in bladder cancer patients and healthy controls were significantly different between Asian and Caucasian patients, but not African patients. The differences between MMP-9 expression in ethnic groups were also evident in the expression rate of MMP-9 identified in histological G1/G2 grade tumors in Asian and Caucasian patients compared with G3 grade tumors, which was not evident in African patients. In conclusion, the present meta-analysis results markedly indicate that MMP-9 expression is associated with clinicopathological features of bladder cancer, suggesting that MMP-9 may be a useful biomarker in the diagnosis and clinical management of bladder cancer, and may be a valuable therapeutic target.

Matrix metalloproteinase-9 overexpression is closely related to poor prognosis in patients with colon cancer

BackgroundMatrix metalloproteinase-9 (MMP-9) is an important member of the matrix metalloproteinase family and is considered to be involved in the invasion and metastasis of cancer cells. This study analyzed the expression of MMP-9 in colon cancer patients and the relationship between this expression and clinicopathological features and survival.MethodsWe immunohistochemically investigated 68 specimens of colon cancer tissues and corresponding distal normal mucosa tissues using MMP-9 antibody. Then, the correlation between MMP-9 expression and clinicopathological features and its prognostic relevance were determined.ResultsThe expression rate of MMP-9 in colon cancer tissues was significantly higher than that in distal normal mucosa (69.1% versus 2.9%, P < 0.001). Significant correlations were only found between high levels of MMP-9 expression and metastasis of lymph nodes and Dukes’ stage. Overexpression of MMP-9 was associated with shorter survival times in univariate analysis. Multivariate analysis confirmed that MMP-9 expression was an independent prognostic factor.ConclusionsMMP-9 is correlated with the metastasis of lymph nodes, and its elevated expression may be an adverse prognostic indicator for the patients of colon cancer.

Expression and significance of MMP-26, TIMP-4 and MMP-9 in diffuse large B-cell lymphoma cells

The aim of this study was to investigate the expression of matrix metalloproteinase 26 (MMP-26), tissue inhibitor of metalloproteinase-4 (TIMP-4) and matrix metalloproteinase 9 (MMP-9) in patients with diffuse large B cell lymphoma (DLBCL) and their correlations with pathogenesis and development of DLBCL. A total of 95 specimens excised from DLBCL patients were prepared. Expression of MMP-26, TIMP-4 and MMP-9 were tested by SABC immunohistochemistry method and its correlation to clinicopathology indexes were analyzed. The results showed that as compared with reactive hyperplasia of lymph nodes, the high expression of MMP-26, TIMP-4 and MMP-9 were found in different types of DLBCL. The positive expression rate of MMP-26 was related to immune typing (P < 0.05). The expression level of MMP-26 in GCB was lower than that in non-GCB, and did not relate to clinical staging, age, sex, diseased region (P > 0.05). The positive expression rate of MMP-9 was related to clinical staging, the positive expression rate of MMP-9 proteins in patient at III and IV stage was obviously higher than that in patients at I and II stage, but did not relate to immune type, age, sex and diseased region of DLBCL (P > 0.05). The expression of TIMP-4 did not relate to immune type, clinical stage, age, sex, disease region (P > 0.05). The expression of MMP-26 in pathologic tissue of DLBCL did not relate to expression of TIMP-4, but positively related to expression of MMP-9 protein (r = 0.486, P < 0.05). It is concluded that MMP-26 and MMP-9 synergically express in DLBCL. MMP-26 may be involve in pathogenesis and invasiveness of DLBCL, the expression of MMP-26 relates to subtypes of DLBCL. The MMP-26 may serve as an indicator for typing of DLBCL and contributes to predict the invasion and metastasis of DLBCL and itself may become a potential target for therapy.

Significance and expression of integrin .BETA.1 and matrix metalloproteinase-9 in human brain glioma

Objective To investigate the expression of integrin β1 and matrix metalloproteinase-9 (MMP-9) and their significances in human brain glioma.Methods The expression levels of Integrin β1 and MMP-9 in 50 cases of human brain glioma tissues and 20 cases of normal brain tissues were detected by using immunohistochemical method.Results The expression rate of Integrin β1 was 42％ (21/50) in brain glioma tissues,and 15％ (3/20) in normal brain tissues (P ＜ 0.01),the expression rate of MMP-9 was 72％ (36/50) in brain glioma tissues,and 15％ (3/20) in normal brain tissues (P ＜0.01).the expressions of Integrin β1 and MMP-9 were related to histological grades of glioma (P ＜0.05),the expressions of Integrin β1 was correlated positively with the expressions level of MMP-9 (r =0.35,P ＜ 0.05).Conclusion The expression of Integrin β1 and MMP-9 are closely correlated with the onset,progression and metastasis of brain glioma. Key words: Immunohistochemical method; Integrin β1; Matrix metalloproteinase-9; Glioma

Significance of expression of chemokine receptor and matrix metalloproteinase in small cell lung cancer

To explore the expressions of CXC chemokine receptor 4 (CXCR4) and matrix metalloproteinase-9 (MMP-9) and examine their correlations with metastasis and prognosis in small cell lung cancer (SCLC). Immunohistochemistry was employed to detect the expressions of CXCR4 and MMP-9 in the tissue samples from 65 SCLC patients treated in Cancer Institute and Hospital Attached to Tianjin Medical University from January 2003 to October 2009. And their correlations with metastasis and prognosis were analyzed by Chi-square test and Kaplan-Meier method and Cox regression. The positive expression rates of CXCR4 and MMP-9 were 100.0% (65/65) and 87.7% (57/65) in SCLC tissues respectively. Significant difference of the expression rate of CXCR4 was found between patients undergoing bone metastasis or not (P = 0.004). But the differences were not significant between brain metastasis or not (P = 0.068) and lymph node metastasis or not (P = 0.085). A high expression rate of MMP-9 was significantly associated with pathological staging (P = 0.048). But the difference between lymph node metastasis or not was not significant (P = 0.085). Univariate analysis suggested that a high expression rate of CXCR4 was significantly correlated with the disease-free survival (DFS) of SCLC patients (P = 0.005). But a high expression rate of MMP-9 was not associated with DFS (P = 0.341). Multivariate analysis suggested that a high expression rate of CXCR4 was an independent prognostic factor for DFS in SCLC. The elevated levels of CXCR4 and MMP-9 are found in SCLC tissues. And the expression rate of CXCR4 may be correlated with bone metastasis, but the correlation is not notable for MMP-9. The expression rate of CXCR4 is an independent prognostic factor for DFS in SCLC.

Expressions of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 and their correlation with metastasis and prognosis in lung cancer

To investigate the expressions of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) and their correlation with metastasis and prognosis in human lung cancer. Immunohistochemical S-P method was used to detect the expression of MMP-9 and TIMP-1 in 65 lung cancer tissues, 35 hyperplastic and dysplastic epithelium from patients with non-cancerous pulmonary diseases, and 30 normal epithelial tissues of the lung. The positive expression rates of MMP-9 in normal tissue, hyperplastic or dysplastic epithelium, and lung cancer tissue were 16.7%(5/30), 42.9%(15/35) and 72.3%(47/65) respectively, whereas the positive rates of TIMP-1 expression in normal tissue, hyperplastic or dysplastic epithelium, and lung cancer tissue were 6.7%(2/30), 28.6%(10/35) and 50.8%(33/65) respectively. Significant differences of the expression rates of MMP-9 and TIMP-1 were found between lung cancer and normal groups, between lung cancer and hyperplasia groups, and between hyperplasia and normal groups (P < 0.05). Small cell carcinoma and adenocarcinoma had higher MMP-9 expression than squamous cell carcinoma (P < 0.025). Expression rate of MMP-9 had negative relation with cell differentiation of lung cancer (P < 0.05), and positive relation with TNM stage (P < 0.025). Between the survival time < 2 years group and ≥2 years groups, both the expressions of MMP-9 and TIMP-1 had significant difference (P < 0.05 ). The expression of MMP-9 was closely related to metastasis of lung cancer (P < 0.005), but the expression of TIMP-1 was not related to metastasis. Overexpression of MMP-9 may appear in precancerous lesion and at the early stage of lung cancer. Activation of MMP-9 gene may be an important factor for oncogenesis of the lung. MMP-9 and TIMP-1 may play important roles in lung cancer invasion and metastasis, their overexpression could act as a reference to evaluate metastasis and unfavourable prognosis of lung cancer.